NCT02857998View on ClinicalTrials.gov

A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

PHASE1CompletedINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

December 27, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions

Mature B-cell Neoplasms

Interventions

DRUG

HMPL-523

Oral administration, once daily

Trial Locations (2)

200032

Fudan University Shanghai Cancer Hospital, Shanghai

Unknown

BeijingCancer Hospital, Beijing

All Listed Sponsors

lead

Hutchison Medipharma Limited

INDUSTRY

NCT02857998 - A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms | Biotech Hunter | Biotech Hunter